Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 9/20 | 0.78 |
| ▸ | THRB | P10828 | 2/20 | 0.56 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | MAP3K14 | Q99558 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15748843 | 0.90 | MAPT (0.64) | MAPTTHRBALDH1A1KDM4ETDP1 | |
| SCHEMBL15748958 | 0.89 | MAPT (0.72) | MAPTTHRBALDH1A1KDM4EHPGD | |
| SCHEMBL13977289 | 0.88 | MAPT (1.00) | MAPTTHRBALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL15748928 | 0.87 | MAPT (0.68) | MAPTTHRBALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL17192440 | 0.87 | MAPT (0.59) | MAPTTHRBALDH1A1KDM4ETDP1 | |
| SCHEMBL15748846 | 0.86 | MAPT (0.58) | MAPTTHRBKDM4ETDP1L3MBTL1 | |
| SCHEMBL15748813 | 0.86 | MAPT (0.58) | MAPTTHRBKDM4ETDP1L3MBTL1 | |
| SCHEMBL15748777 | 0.85 | MAPT (0.56) | MAPTTHRBMAP3K14 | |
| SCHEMBL15748942 | 0.85 | MAPT (0.71) | MAPTTHRBALDH1A1MAPK1SMN1; SMN2 | |
| SCHEMBL15748849 | 0.84 | MAPT (0.56) | MAPTTHRBALDH1A1MAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9676779-B2 | Small molecule CFTR correctors | DISCOVERYBIOMED, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-9676779-B2 | Small molecule CFTR correctors | DISCOVERYBIOMED, INC. (US) | 2017-06-13 | — | — | US | disclosed |
| US-20150299206-A1 | SMALL MOLECULE CFTR CORRECTORS | DISCOVERYBIOMED, INC. (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150299206-A1 | SMALL MOLECULE CFTR CORRECTORS | DISCOVERYBIOMED, INC. (US) | 2015-10-22 | — | — | US | disclosed |
| WO-2014081820-A1 | SMALL MOLECULE CFTR CORRECTORS | DISCOVERYBIOMED, INC. (US) | 2014-05-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150299206-A1 | SMALL MOLECULE CFTR CORRECTORS | CFTR, CLCN2, SLC26A4 | MAPT 4258/4885THRB 2036/4885ALDH1A1 3475/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.